Chetan Madhurima R, Barrett Tristan, Gallagher Ferdia A
School of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, United Kingdom.
Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
World J Radiol. 2017 Sep 28;9(9):350-358. doi: 10.4329/wjr.v9.i9.350.
To determine the significance and need for investigation of incidental prostatic uptake in men undergoing F-labelled fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) for other indications.
Hospital databases were searched over a 5-year period for patients undergoing both PET/CT and prostate magnetic resonance imaging (MRI). For the initial analysis, the prostate was divided into six sectors and suspicious or malignant sectors were identified using MRI and histopathology reports respectively. Maximum and mean F-FDG standardised uptake values were measured in each sector by an investigator blinded to the MRI and histopathology findings. Two age-matched controls were selected per case. Results were analysed using a paired test and one-way ANOVA. For the second analysis, PET/CT reports were searched for prostatic uptake reported incidentally and these patients were followed up.
Over a 5-year period, 15 patients underwent both PET/CT and MRI and had biopsy-proven prostate cancer. Malignant prostatic sectors had a trend to higher F-FDG uptake than benign sectors, however this was neither clinically nor statistically significant (3.13 ± 0.58 2.86 ± 0.68, > 0.05). F-FDG uptake showed no correlation with the presence or histopathological grade of tumour. F-FDG uptake in cases with prostate cancer was comparable to that from age-matched controls. Forty-six (1.6%) of 2846 PET/CTs over a 5-year period reported incidental prostatic uptake. Of these, 18 (0.6%) were investigated by PSA, 9 (0.3%) were referred to urology, with 3 (0.1%) undergoing MRI and/or biopsy. No cases of prostate cancer were diagnosed in patients with incidental F-FDG uptake in our institute over a 5-year period.
F-FDG uptake overlaps significantly between malignant and benign prostatic conditions. Subsequent patient management was not affected by the reporting of incidental focal prostatic uptake in this cohort.
确定在因其他指征接受F标记的氟脱氧葡萄糖(F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)的男性中,偶然前列腺摄取的研究意义及必要性。
对医院数据库进行为期5年的检索,查找同时接受PET/CT和前列腺磁共振成像(MRI)的患者。在初始分析中,将前列腺分为六个区域,分别使用MRI和组织病理学报告确定可疑或恶性区域。由对MRI和组织病理学结果不知情的研究人员在每个区域测量最大和平均F-FDG标准化摄取值。每个病例选取两名年龄匹配的对照。使用配对检验和单因素方差分析对结果进行分析。在第二次分析中,检索PET/CT报告中偶然报告的前列腺摄取情况,并对这些患者进行随访。
在5年期间,15例患者同时接受了PET/CT和MRI检查,且活检证实患有前列腺癌。恶性前列腺区域的F-FDG摄取有高于良性区域的趋势,但在临床和统计学上均无显著差异(3.13±0.58对2.86±0.68,P>0.05)。F-FDG摄取与肿瘤的存在或组织病理学分级无关。前列腺癌病例中的F-FDG摄取与年龄匹配的对照相当。在5年期间的2846例PET/CT检查中,有46例(1.6%)报告了偶然的前列腺摄取。其中,18例(0.6%)进行了前列腺特异性抗原(PSA)检查,9例(0.3%)转诊至泌尿外科,3例(0.1%)接受了MRI和/或活检。在我们研究所的5年期间,偶然F-FDG摄取的患者中未诊断出前列腺癌病例。
恶性和良性前列腺疾病之间的F-FDG摄取有显著重叠。在该队列中,偶然局灶性前列腺摄取的报告并未影响后续患者的管理。